CD5 overexpression

P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023

P2, N=50, Not yet recruiting, PETHEMA Foundation

The complexity of the phenotypic signature of lymphoblasts at diagnosis of B ALL is illustrated by the variability in the expression of LAP antigens. Knowledge of the expression levels of these markers in normal leukocytes and during normal B differentiation is crucial for an optimal interpretation of diagnostic cytometry results and serves as a basis for the biological follow-up of B ALL.

Acknowledgments. GB was supported by Fundación Alfonso Martín Escudero.

In conclusion, our data suggest CD56 levels as an important determinant of sensitivity to DARA-based therapies. Moreover, our results suggest the next-generation NAMPT inhibitors as an additional therapeutic strategy for CD56-expressing MM patients.

Conclusions T cell-depleted allo-HSCT can be a viable treatment platform for treating relapsed NBL when combined with adoptive transfer of ex-vivo-stimulated NK cells and TIM 3 checkpoint blockade. These studies demonstrate that multi-modal approaches incorporating combination immunotherapy are needed for NBL and that immunotherapies that enhance NK cell function should be prioritized.

Additionally, next-generation sequencing data revealed SSP was significantly associated with the KMT2D mutation and had different genetic mutation profiles from non-SSP. In conclusion, SSP may represent morphologic characteristics of aggressiveness in DEL.

CD59, which acts as a complement regulator, may protect the NMJ from complement attack. Our findings could provide a basis for further research that investigates the underlying pathogenesis in MG and the immunomodulating interactions of the muscle cells.

The addition of metformin significantly decreased the M2 proportion and the CD36 expression level in the coculture systems, indicating that metformin could target altered lipid metabolism and decrease M2 macrophages in DLBCL, especially in CD5+ non-DE lymphoma. In conclusion, enhanced lipid metabolism and M2 macrophage activation contributed to the immunosuppressive tumor microenvironment and could be potential therapeutic targets in CD5+ non-DE DLBCL.

A prostatic adenocarcinoma can extremely rarely be in a coexistence with undiagnosed lymphoproliferative disease, such as non Hodgkin mantle cell lymphoma in our case. This lymphoma is usually synchronously present with plasma cell dyscrasia or granulomatous diseases such as sarcoidosis. It can also occur with metastasis from a diferent anatomical site, but in the same lymph node.

The MTT test and trypan blue staining showed that the microspheres could promote the apoptosis of oral squamous cell carcinoma and had a significant difference (p < 0.01). In this study, the regulatory effect of the microspheres on OSCC cells was investigated at the cellular level, and its therapeutic effect on OSCC was discussed, which provided a new perspective for the targeted therapy of OSCC.

In conclusion, our study defines an effective threshold for therapeutic intervention in CD56-expressing MM patients. Moreover, our data pioneer the use of CREB1/RSK2 inhibition in CD56-expressing MM cells, either as single agents or in combination with lenalidomide, suggesting that CD56 can be a prognostic and predictive factor of response in MM.

Therefore, high expression of CD52 may negatively regulate the infiltration of M2 macrophages but accelerate the infiltration of anti-cancer immune cells, and thus, high expression of CD52 may have a protective effect in breast cancer patients. CD52 can increase the infiltration of anti-cancer immune cells but inhibit the infiltration of M2 macrophages, thereby improving the prognosis of breast cancer patients.